A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

作者：Tsuya Asuka^*; Kurata Takayasu; Tamiya Akihiro; Okamoto Isamu; Ueda Shinya; Sakai Daisuke; Sugimoto Naotoshi; Matsumoto Koji; Goto Isao; Yamamoto Nobuyuki; Fukuoka Masahiro; Nakagawa Kazuhiko

来源：Investigational New Drugs, 2013, 31(6): 1568-1572.

DOI：10.1007/s10637-013-0014-0

• Cisplatin
• S-1
• Chemotherapy
• Carcinoma of unknown primary site

Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m(2)) twice a day on days 1-21, and intravenous CDDP (60 mg/m(2)) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 % and 80.4 %, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 %, 13.0 %, and 2.2 % of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.

• 出版日期2013-12